Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763180 | 0.90 | GABRA1 (0.40) | GABRA1GABRB2TSHRCA1CA2 | |
| SCHEMBL16771350 | 0.87 | TSHR (0.46) | TSHRCA1CA2ALDH1A1KDM5A | |
| SCHEMBL16884620 | 0.86 | GABRA1 (0.38) | GABRA1GABRB2TSHRCA1CA2 | |
| SCHEMBL22447106 | 0.86 | TSHR (0.36) | GABRA1GABRB2TSHRARLMNA | |
| SCHEMBL16953662 | 0.86 | TSHR (0.36) | GABRA1GABRB2TSHRCA1CA2 | |
| SCHEMBL16097833 | 0.86 | GABRA1 (0.42) | GABRA1GABRB2TSHRCA1CA2 | |
| SCHEMBL28799888 | 0.83 | ESR2 (0.40) | GABRA1GABRB2TSHRCA1CA2 | |
| SCHEMBL16959910 | 0.83 | ALDH1A1 (0.37) | TSHRARALDH1A1KDM5ANPSR1 | |
| SCHEMBL16960684 | 0.83 | S1PR1 (0.38) | GABRA1GABRB2TSHR | |
| SCHEMBL28044154 | 0.83 | GABRA1 (0.39) | GABRA1GABRB2TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331704-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-1150970-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047572-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2000-08-17 | — | — | WO | disclosed |
| US-4136156-A | HYDROGEN CYANIDE, HYDROGENATION CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331704-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | NR2E3, NR2E1, NR0B2 | GABRA1 2476/4885GABRB2 3340/4885TSHR 2360/4885 |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | GABRA1 293/4885GABRB2 876/4885TSHR 1871/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | GABRA1 2922/4885GABRB2 2882/4885TSHR 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.